应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
STSA Satsuma Pharmaceuticals, Inc.
退市 12-19 14:18:10 EST
1.10
+0.00
0.00%
最高
1.10
最低
1.10
成交量
0.00
今开
1.10
昨收
1.10
日振幅
0.00%
总市值
3,647万
流通市值
1,672万
总股本
3,315万
成交额
194.10万
换手率
0.00%
流通股本
1,520万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
舒泰神：STSA-1301皮下注射液取得Ia期临床研究总结报告
经济观察报 · 08-08
舒泰神：STSA-1301皮下注射液取得Ia期临床研究总结报告
舒泰神(300204.SZ)：STSA-1301皮下注射液取得Ia期临床研究总结报告
智通财经网 · 08-08
舒泰神(300204.SZ)：STSA-1301皮下注射液取得Ia期临床研究总结报告
舒泰神：取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。
美港电讯 · 08-08
舒泰神：取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。
舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。
格隆汇 · 06-18
舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。
【舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告】金十数据6月18日讯，舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。
美港电讯 · 06-18
【舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告】金十数据6月18日讯，舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。
舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告
智通财经 · 06-18
舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告
【舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告】智通财经APP讯，舒泰神(300204.
智通财经 · 06-18
【舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告】智通财经APP讯，舒泰神(300204.
【舒泰神：终止部分在研项目临床试验】金十数据3月25日讯，舒泰神公告，公司基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作。
美港电讯 · 03-25
【舒泰神：终止部分在研项目临床试验】金十数据3月25日讯，舒泰神公告，公司基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作。
舒泰神：终止部分在研项目临床试验舒泰神公告，基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作
格隆汇 · 03-25
舒泰神：终止部分在研项目临床试验舒泰神公告，基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作
暂无数据
公司概况
公司名称：
Satsuma Pharmaceuticals, Inc.
所属市场：
NASDAQ
上市日期：
--
主营业务：
Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立，是一家临床阶段的生物制药公司，开发一种治疗偏头痛急性治疗的新型治疗药物。
发行价格：
--
{"stockData":{"symbol":"STSA","market":"US","secType":"STK","nameCN":"Satsuma Pharmaceuticals, Inc.","latestPrice":1.1,"timestamp":1686168000000,"preClose":1.1,"halted":4,"volume":0,"delay":0,"floatShares":15203712,"shares":33152498,"eps":-1.999338,"marketStatus":"退市","marketStatusCode":2,"change":0,"latestTime":"12-19 14:18:10 EST","open":1.1,"high":1.1,"low":1.1,"amount":1940959.886414,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.999338,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734642000000},"adr":0,"listingDate":1568347200000,"adjPreClose":1.1,"volumeRatio":0},"requestUrl":"/m/hq/s/STSA/tweets","defaultTab":"tweets","newsList":[{"id":"2457165663","title":"舒泰神：STSA-1301皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2457165663","media":"经济观察报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457165663?lang=zh_cn&edition=full","pubTime":"2024-08-08 20:18","pubTimestamp":1723119514,"startTime":"0","endTime":"0","summary":"经济观察网讯 8月8日，舒泰神（300204）在深交所公告，公司取得 STSA-1301 皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。药品适应症为原发性免疫性血小板减少症。（实习记者 李贵民 编辑 王俊勇）...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/ObiYb3xdFnlcWLaIQ93fEXL60FWoV3KTMN05Qrl53uWGYAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/ObiYb3xdFnlcWLaIQ93fEXL60FWoV3KTMN05Qrl53uWGYAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240808A093Y800","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240808A093Y800","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["STSA","BK4007"],"gpt_icon":0},{"id":"2457366595","title":"舒泰神(300204.SZ)：STSA-1301皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2457366595","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457366595?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:51","pubTimestamp":1723107097,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告，近日，公司取得STSA-1301皮下注射液用于治...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/15.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/15.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0028","BK4007","BK0046","300204","STSA"],"gpt_icon":0},{"id":"2457365804","title":"舒泰神：取得STSA-1301皮下注射液用于治疗原发性免疫性血小板减少症的Ia期临床研究总结报告。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457365804","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457365804?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:39","pubTimestamp":1723106353,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["STSA","BK0028","BK4007","BK0046","BK0239","300204"],"gpt_icon":0},{"id":"2444610332","title":"舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444610332","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444610332?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:18","pubTimestamp":1718698682,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK0239","BK0028","BK4007","BK1583","BK0046","03347","STSA","BK1576","300204"],"gpt_icon":0},{"id":"2444108739","title":"【舒泰神：STSA-1201皮下注射液取得Ia期临床研究总结报告】金十数据6月18日讯，舒泰神公告，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444108739","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444108739?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:16","pubTimestamp":1718698573,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","STSA","BK1141","BK4007","03347","300204","BK1576","BK0046","BK0028","BK0239"],"gpt_icon":0},{"id":"2444108417","title":"舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2444108417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444108417?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:08","pubTimestamp":1718698111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，舒泰神(300204.SZ)公告，近日，公司取得STSA-1201皮下注射液用于治疗哮喘适应症的Ia期临床研究总结报告。I期临床试验结果显示，在方案设计的剂量范围内，STSA-1201皮下注射液在健康受试者中单次给药的安全性和耐受性良好，未检出抗药抗体，且药物代谢呈线性药代动力学特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["STSA","300204","BK4007","BK0239","BK0028","BK0046"],"gpt_icon":0},{"id":"2444108411","title":"【舒泰神(300204.SZ)STSA-1201皮下注射液取得Ia期临床研究总结报告】智通财经APP讯，舒泰神(300204.","url":"https://stock-news.laohu8.com/highlight/detail?id=2444108411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444108411?lang=zh_cn&edition=full","pubTime":"2024-06-18 16:08","pubTimestamp":1718698111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["300204","BK0239","BK4007","BK0046","STSA","BK0028"],"gpt_icon":0},{"id":"2422598691","title":"【舒泰神：终止部分在研项目临床试验】金十数据3月25日讯，舒泰神公告，公司基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作。","url":"https://stock-news.laohu8.com/highlight/detail?id=2422598691","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422598691?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:06","pubTimestamp":1711357562,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["STSA","BK4588","BNTX","03347","300204","BK4007","BK4548","BK4551","BK0239","BK4568","BK0028","BK4139","BK4535","BK1141","BK4585","BK1583","BK0046","BK1576"],"gpt_icon":0},{"id":"2422607965","title":"舒泰神：终止部分在研项目临床试验舒泰神公告，基于当前新冠疫情形势，结合年度审计工作开展，对公司研发项目进行了梳理，经审慎判断，决定终止BDB-001注射液、STSA-1002注射液、STSA-1005注射液、STSA-1002和STSA-1005联合用药项目在COVID-19适应症方向的研究工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2422607965","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2422607965?lang=zh_cn&edition=full","pubTime":"2024-03-25 16:51","pubTimestamp":1711356691,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4548","BK4535","BK4568","BK0239","BK4585","STSA","BK1141","BNTX","03347","300204","BK1583","BK4007","BK4139","BK4588","BK0046","BK1576","BK4551","BK0028"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.satsumarx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Satsuma Pharmaceuticals, Inc.于2016年6月21日在特拉华州注册成立，是一家临床阶段的生物制药公司，开发一种治疗偏头痛急性治疗的新型治疗药物。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.18106},{"month":2,"riseRate":0.5,"avgChangeRate":-0.018348},{"month":3,"riseRate":0.25,"avgChangeRate":-0.137},{"month":4,"riseRate":0.5,"avgChangeRate":0.08762},{"month":5,"riseRate":0.25,"avgChangeRate":0.034529},{"month":6,"riseRate":1,"avgChangeRate":0.195405},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.113868},{"month":8,"riseRate":0.333333,"avgChangeRate":0.112636},{"month":9,"riseRate":0,"avgChangeRate":-0.31806},{"month":10,"riseRate":0.25,"avgChangeRate":-0.048014},{"month":11,"riseRate":0.5,"avgChangeRate":-0.101074},{"month":12,"riseRate":0.5,"avgChangeRate":0.052715}],"exchange":"NASDAQ","name":"Satsuma Pharmaceuticals, Inc.","nameEN":"Satsuma Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Satsuma Pharmaceuticals, Inc.,STSA,Satsuma Pharmaceuticals, Inc.股票,Satsuma Pharmaceuticals, Inc.股票老虎,Satsuma Pharmaceuticals, Inc.股票老虎国际,Satsuma Pharmaceuticals, Inc.行情,Satsuma Pharmaceuticals, Inc.股票行情,Satsuma Pharmaceuticals, Inc.股价,Satsuma Pharmaceuticals, Inc.股市,Satsuma Pharmaceuticals, Inc.股票价格,Satsuma Pharmaceuticals, Inc.股票交易,Satsuma Pharmaceuticals, Inc.股票购买,Satsuma Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Satsuma Pharmaceuticals, Inc.(STSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Satsuma Pharmaceuticals, Inc.(STSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}